Similar articles

• Biochemical mechanisms involved in the beta-blocker-induced changes in serum lipoproteins.

  Lijnen P. Lijnen P. Am Heart J. 1992 Aug;124(2):549-56. doi: 10.1016/0002-8703(92)90634-8. Am Heart J. 1992. PMID: 1353298 No abstract available.
• Lipid profile improvement following celiprolol.

  Herrmann JM, von Heyman F, Freischütz G. Herrmann JM, et al. J Int Med Res. 1988;16 Suppl 1:39A-46A. J Int Med Res. 1988. PMID: 2906016
• [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension].

  Podzolkov VI, Mozharova LG. Podzolkov VI, et al. Kardiologiia. 2002;42(10):22-6. Kardiologiia. 2002. PMID: 12494052 Russian.
• Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.

  Lamon KD. Lamon KD. Cardiovasc Drugs Ther. 1991 Jan;4 Suppl 6:1291-5. doi: 10.1007/BF00114236. Cardiovasc Drugs Ther. 1991. PMID: 1672605 Review.
• [The third generation of b-blockers: new possibilities ].

  Iagenskiĭ AV, Barsukov BP. Iagenskiĭ AV, et al. Kardiologiia. 1992;32(11-12):98-103. Kardiologiia. 1992. PMID: 1363672 Review. Russian. No abstract available.